ELESTAT Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Elestat, and when can generic versions of Elestat launch?

Elestat is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in ELESTAT is epinastine hydrochloride. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the epinastine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elestat

A generic version of ELESTAT was approved as epinastine hydrochloride by BRECKENRIDGE on March 14^th, 2011.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ELESTAT?
What are the global sales for ELESTAT?
What is Average Wholesale Price for ELESTAT?

Summary for ELESTAT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	107
Clinical Trials:	2
Patent Applications:	3,491
Drug Prices:	Drug price information for ELESTAT
What excipients (inactive ingredients) are in ELESTAT?	ELESTAT excipients list
DailyMed Link:	ELESTAT at DailyMed

Drug patent expirations by year for ELESTAT

Recent Clinical Trials for ELESTAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aston University	Phase 4
University of Worcester	Phase 4
Merck Sharp & Dohme Corp.	Phase 4

See all ELESTAT clinical trials

Paragraph IV (Patent) Challenges for ELESTAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ELESTAT	Ophthalmic Solution	epinastine hydrochloride	0.05%	021565	1	2008-10-14

US Patents and Regulatory Information for ELESTAT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ELESTAT	epinastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021565-001	Oct 16, 2003		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ELESTAT

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	ELESTAT	epinastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021565-001	Oct 16, 2003	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ELESTAT

See the table below for patents covering ELESTAT around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	1292752		⤷ Sign Up
Serbia	50173	UPOTREBA EPINASTINA ZA LEČENJE ALERGIJSKOG RINITISA/KONJUKTIVITISA (USE OF EPINASTIN FOR TREATMENT OF ALLERGIC RHINITIS/CONJUNCTIVITIS)	⤷ Sign Up
Norway	20022201		⤷ Sign Up
Saudi Arabia	1529	محاليل تحتوي على ابيناستين Epinastin	⤷ Sign Up
Hungary	0203773		⤷ Sign Up
Croatia	P20020404	OTOPINE KOJE SADRŽE EPINASTIN (SOLUTIONS CONTAINING EPINASTINE)	⤷ Sign Up
Germany	50014041		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ELESTAT

Recent Clinical Trials for ELESTAT

Paragraph IV (Patent) Challenges for ELESTAT

Make Better Decisions: Try a trial or see plans & pricing